New Approaches to Meet Patients’ Needs in Clinical Practice

Summary of Presentations from The Menarini Group-Supported Satellite Symposium, held at the 4th EHMTIC, Copenhagen, Denmark, on 19th September 2014

Chairpersons: E. Anne MacGregor,1 Stefan Evers2
Speakers: Carlo Lisotto,3 E. Anne MacGregor, Stefan Evers

1. Barts Sexual Health Centre, St Bartholomew’s Hospital and Centre for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK
2. University of Münster, Münster; Department of Neurology, Krankenhaus Lindenbrunn, Coppenbrügge, Germany
3. Headache Centre, Hospital of Pordenone and Headache Centre, Department of Neurosciences, University of Padua, Padua, Italy

Disclosure: Prof MacGregor has received professional fees from Bayer Healthcare, Curelator Inc., GlaxoSmithKline, The Menarini Group, and PPFA. Prof Evers received honoraria and research grants within the past 5 years from AGA Medical (now St Jude), Allergan, Almirall, AstraZeneca, Berlin Chemie, CoLucid, Desitin, Eisai, GlaxoSmithKline, Ipsen Pharma, The Menarini Group, MSD, Novartis, Pfizer, ReckittBenckiser, and UCB. Prof Lisotto has received professional fees from Allergan, Almirall, Astra-Zeneca, Bayer, GlaxoSmithKline, Janssen-Cilag, The Menarini Group, MSD, Pfizer, and Roche.
Acknowledgements: Writing assistance was provided by Dr Tom Priddle of Apothecom Scopemedical Ltd.
Support: The publication of this article was funded by The Menarini Group. The views and opinions expressed are those of the authors and not necessarily of The Menarini Group.
Citation: EMJ Neurol. 2014;2(Suppl 1):2-9.

Meeting Summary

Migraine is a primary headache disorder affecting up to four in ten women and up to two in ten men, mostly before the age of 35 years.1 By the age of 30, migraine is 3-times more prevalent in women than in men.1 The effects of migraine vary considerably, ranging from minimal disruption of daily activities to severe disability.1 Migraine without aura (MWoA) is most common, followed by migraine with aura (MWA).1 Attacks typically last 4-72 hours, with two or more specific features (unilateral location, pulsating, moderate-to-severe pain intensity, or aggravation by routine physical activity) during the attack. Migraine attacks are also accompanied by at least one of nausea, vomiting, and photophobia and phonophobia.1

It is 25 years since triptans first became available on prescription. Although their safety and efficacy is well established, there is still a great deal of ongoing research into the nuances of their use in treating patients with specific needs. Frovatriptan, in common with other triptans, is a serotonin (5-hydroxytryptamine, 5-HT) 1B/1D receptor agonist.1 Frovatriptan also shows moderate affinity for 5-HT7 receptors,1 resulting in more potent contraction of cerebral arteries than coronary arteries, with the potential for good efficacy and low risk of unwanted effects.1 Frovatriptan is distinctive from other triptans due to its half-life of 26 hours, which confers a longer duration of action.1

Download (PDF, 136KB)

Comments are closed.